MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

Topic

November 20, 2017

Pfizer does not deserve the patent it was granted in August on its pneumonia vaccine Prevnar13 (PCV13), said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF). MSF is set to argue tomorrow in the High Court of Delhi that it should be overturned because the patent doesn’t meet the standards laid out in India’s Patents Act.

October 13, 2017

The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières(MSF) filed a petition before the High Court of Delhi today to overturn a patent granted to Pfizer pharmaceutical corporation on the pneumococcal conjugate vaccine (PCV).

August 22, 2017

Hopes for improved access to an affordable pneumococcal conjugate vaccine (PCV) that protects both children and adults from pneumonia was dealt a major blow after the Indian patent office granted a patent to the U.S. pharmaceutical corporation Pfizer.

July 25, 2017

At a time when life-saving antiretrovirals are more widely available than ever, an unacceptably high number of people are still dying of AIDS in sub-Saharan Africa.

July 25, 2017

Greater global attention is needed to prevent and treat AIDS, as too many patients are dying despite the availability of antiretroviral treatment.

June 26, 2017

As U.S. President Donald Trump and Indian Prime Minister Narendra Modi meet at the White House today, Doctors Without Borders/Médecins Sans Frontières (MSF) warned that U.S. pressure on India to change its drug regulatory and patent system could result in millions of people in the U.S. and around the world losing their lifeline of affordable medicines. As an international medical humanitarian organization that relies on affordable generic medicines produced in India to run its medical programs in more than 60 countries, MSF urged Modi to stand strong and protect India’s role as the “pharmacy of the developing world.”

April 06, 2017

Doctors Without Borders/Médecins Sans Frontières (MSF) began working in Likoni, Kenya, in February 2016, collaborating with the Mombasa County Department of Health. While MSF renovates and upgrades the brick and mortar maternity hospital in Likoni, staff provide life-saving care for mothers and babies inside a temporary shipping container structure—the Mrima Health Center. 

February 23, 2017

At its clinic in Nairobi, Kenya, Doctors Without Borders/Médecins Sans Frontières (MSF) offers victims of sexual violence psychological and medical care, social support, and legal advice.

February 14, 2017

NEW YORK/NEW DELHI, FEBRUARY 14, 2017—Five new challenges against flawed patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral (DAA) medicines, including sofosbuvir, daclatasvir and velpatasvir, and increase access for millions of people.

Pages

November 20, 2017

Pfizer does not deserve the patent it was granted in August on its pneumonia vaccine Prevnar13 (PCV13), said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF). MSF is set to argue tomorrow in the High Court of Delhi that it should be overturned because the patent doesn’t meet the standards laid out in India’s Patents Act.

October 13, 2017

The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières(MSF) filed a petition before the High Court of Delhi today to overturn a patent granted to Pfizer pharmaceutical corporation on the pneumococcal conjugate vaccine (PCV).

August 22, 2017

Hopes for improved access to an affordable pneumococcal conjugate vaccine (PCV) that protects both children and adults from pneumonia was dealt a major blow after the Indian patent office granted a patent to the U.S. pharmaceutical corporation Pfizer.

July 25, 2017

At a time when life-saving antiretrovirals are more widely available than ever, an unacceptably high number of people are still dying of AIDS in sub-Saharan Africa.

July 25, 2017

Greater global attention is needed to prevent and treat AIDS, as too many patients are dying despite the availability of antiretroviral treatment.

June 26, 2017

As U.S. President Donald Trump and Indian Prime Minister Narendra Modi meet at the White House today, Doctors Without Borders/Médecins Sans Frontières (MSF) warned that U.S. pressure on India to change its drug regulatory and patent system could result in millions of people in the U.S. and around the world losing their lifeline of affordable medicines. As an international medical humanitarian organization that relies on affordable generic medicines produced in India to run its medical programs in more than 60 countries, MSF urged Modi to stand strong and protect India’s role as the “pharmacy of the developing world.”

April 06, 2017

Doctors Without Borders/Médecins Sans Frontières (MSF) began working in Likoni, Kenya, in February 2016, collaborating with the Mombasa County Department of Health. While MSF renovates and upgrades the brick and mortar maternity hospital in Likoni, staff provide life-saving care for mothers and babies inside a temporary shipping container structure—the Mrima Health Center. 

February 23, 2017

At its clinic in Nairobi, Kenya, Doctors Without Borders/Médecins Sans Frontières (MSF) offers victims of sexual violence psychological and medical care, social support, and legal advice.

February 14, 2017

NEW YORK/NEW DELHI, FEBRUARY 14, 2017—Five new challenges against flawed patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral (DAA) medicines, including sofosbuvir, daclatasvir and velpatasvir, and increase access for millions of people.

Pages